Alcon Reaches 175 Million IOL Implants, PanOptix Surpasses 4 Million Worldwide
Alcon surpassed 175 million global IOL implants, including over 6 million presbyopia-correcting lenses such as PanOptix and Vivity. PanOptix alone has exceeded 4 million implants with a 99% patient satisfaction rate, while PanOptix Pro offers 94% light utilization and reduced scatter for enhanced visual outcomes.
1. Record Global Implant Volumes
Alcon has achieved over 175 million intraocular lens implants worldwide, averaging one implant every four seconds, and has recorded more than 6 million presbyopia-correcting lens procedures since 2015.
2. Expansion of Premium IOL Portfolio
The company’s PanOptix trifocal lenses have surpassed 4 million implants with a 99% patient satisfaction rate, while PanOptix Pro delivers 94% light utilization and reduced scatter; Vivity extended-depth-of-focus lenses have reached over 2 million implants.
3. Strategic Outlook and Pipeline
Alcon plans to introduce new IOL technologies in key markets later this year pending regulatory approvals, leveraging its 30-year IOL experience and broad geographic reach to drive continued growth and address unmet vision needs.